Bolt Biotherapeutics Acquires Prana Therapies in Reverse Merger, Raises $120 Million

What happened

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a Redwood City, California-based drug developer, acquired Prana Therapies, Inc. on October 23, 2026, according to an 8-K filing with the SEC. The deal was structured as a merger in which Prana became a wholly owned subsidiary of Bolt. The filing says the merger is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Under the merger agreement, Bolt issued Prana's stockholders 430,746 shares of Bolt common stock and 16,360.929 shares of a new Series D Non-Voting Convertible Preferred Stock. Each Series D share is convertible into 1,000 shares of common stock. Bolt also assumed Prana's stock options, converting them into options to buy Bolt common stock.

On the same day, Bolt entered a securities purchase agreement to sell 13,995.311 Series D preferred shares, plus warrants to buy additional preferred or common shares equal to 50% of the preferred purchased, for $120 million in gross proceeds. Bolt expects that financing to close October 26, 2026, subject to customary conditions. The warrants would bring in roughly $60 million more if exercised in full for cash, though the filing states there is no assurance any warrants will be exercised.

The ownership math in the filing is the clearest sign of who controls the combined company. Before the financing, assuming conversion of the Series D, Bolt's pre-deal stockholders would hold about 11.8% of the company and former Prana holders about 88.2%. After the financing, Bolt's pre-deal holders would hold about 6.9%, former Prana holders about 51.7%, and the new investors about 41.4%, all on a fully diluted basis.

Bolt's board unanimously approved the merger, and the filing states the deal did not require approval of Bolt stockholders. Bolt has agreed to hold stockholder meetings to seek approval of the preferred conversion and related Nasdaq matters, a possible charter amendment to increase authorized common shares, and a possible reverse stock split at a ratio between 1-for-2 and 1-for-12 for the purpose of maintaining Nasdaq listing compliance.

In connection with the deal, certain Bolt officers, directors and stockholders holding 8.4% of pre-transaction common shares signed support agreements to vote for those proposals. Certain Prana holders and Bolt insiders signed 180-day lock-up agreements covering their shares.

Bolt's stock closed at $6.27 on the event date, up 49.64% from the prior close of $4.19, on volume of 12.76 million shares against an average of about 29,190 — roughly 437 times normal volume, according to the price data.

What Bolt and Prana are

Bolt Biotherapeutics is a clinical-stage biopharmaceutical company, listed in the filing under the standard industrial classification for pharmaceutical preparations. It trades on the Nasdaq Capital Market under the ticker BOLT.

The filing identifies Prana Therapies as a Delaware corporation but does not describe Prana's business, its pipeline, or its financial condition. The only product reference in the filing text is to "PRA-216" and a "Program 2 Phase 1 (IL-31 bispecific)" — an antibody-like drug candidate that the warrants' expiration terms are tied to. The sources provided do not explain what Prana's programs treat or why Bolt chose to acquire it.

What this means

An 8-K is the form a U.S. public company files with the SEC to disclose material events between quarterly reports. The item numbers on this filing map to what happened: Item 1.01 is entry into a material agreement (the merger agreement and the securities purchase agreement), Item 2.01 is completion of an acquisition, Item 3.02 is an unregistered sale of equity (the private placement), Item 5.02 is a director or officer change, Item 5.03 is an amendment to the charter or bylaws (the certificate of designation for the Series D preferred), and Item 7.01 is a Regulation FD disclosure.

The structure here is what the industry calls a reverse merger. Bolt is the public company and the legal acquirer, but its original shareholders end up with a small minority of the combined company — about 6.9% after the financing — while Prana's former owners hold about 51.7%. In practice, Prana's business becomes the dominant part of the public company, which is why deals like this are often described as Prana "going public" through Bolt's listing.

The Series D preferred stock is a hybrid security. It pays no stated dividend in the filing and does not vote, but each share converts into 1,000 common shares once stockholders approve the conversion. The $120 million private placement was priced at that same conversion ratio. Preferred stock is sold privately here under Section 4(a)(2) of the Securities Act and Rule 506, exemptions that let a company raise money from institutional investors without a public offering and its associated registration process.

The warrants are sweeteners attached to the financing: the right, not the obligation, to buy more Series D shares or common stock later. Their expiry is tied to a specific clinical milestone — Bolt's first public disclosure of early human trial data for its IL-31 bispecific program, including at least two dosing cohorts with at least eight weeks of follow-up — or June 30, 2028, whichever comes first. That structure gives the investors an incentive tied to the drug program's progress rather than a fixed calendar date alone.

Because the shares issued in the merger and the private placement were not registered, Bolt must file a resale registration statement with the SEC within 75 days of the financing closing, and use reasonable best efforts to have it declared effective within five business days if the SEC does not review it, or 60 days if it does. Registration matters because it lets the new holders sell their shares publicly; the 180-day lock-ups on insiders and certain Prana holders restrict some of those sales in the near term.

The reverse split proposal and the request to increase authorized shares are both mechanical consequences of issuing a large number of new shares: the company needs enough authorized stock to cover the conversion, and the split would raise the per-share price if Nasdaq's minimum bid requirement becomes an issue. The filing does not state that Bolt is currently out of compliance, only that the split would be for maintaining compliance.

The filing does not explain why Bolt and Prana agreed to this transaction, why the deal closed on these terms, or what the combined company's strategy will be. The stock's 49.64% move and the roughly 437-fold jump in volume indicate the market reacted strongly to the disclosure, but the sources provided do not attribute the move to a specific cause beyond the announcements themselves.